Monoclonal Antibody Therapies for HPV-Associated Cervical Cancer: A Literature Review

Main Article Content

Authors

Dariatul Janah
Andi Yasmon
Keywords:
Array, Array, Array

Abstract

Text size

Cervical cancer is a malignancy in gynecology attributable to human papillomavirus (HPV) infection with high prevalence and mortality caused by persistent infections of hr-HPV 16 and 18. HPV with various virulence factors can evade the immune system and integrate its genetic material into the host cell DNA. HPV replication only occurs in differentiated cells in the upper layer of the mucosal epithelium or skin developing into cancer. Globally, approximately 70% of patients diagnosed with cervical cancer present at an advanced or late stage causing therapy to be ineffective. The use of HPV-specific monoclonal antibodies for therapy with cervical cancer, as an alternative or complement will give new insight into managing the patients. The development of monoclonal antibodies having potential as an alternative therapy began to be used as a therapy in the advanced, recurrent, persistent or metastatic cervical cancer. This review specifically discusses monoclonal antibodies that have been approved by FDA for therapy against cervical cancer. In clinical trials, adding bevacizumab to combination chemotherapy extended median overall survival by 3.7 months in patients with recurrent, persistent, or metastatic cervical cancer. Pembrolizumab significantly prolonged progression-free and overall survival compared to placebo when combine to chemotherapy (with or without bevacizumab) in similar patient populations. Likewise, tisotumab-vedotin demonstrated greater over chemotherapy as second-line or third-line therapy for recurrent cervical cancer. Therefore, this article review aims to describe the types and roles of monoclonal antibodies that have potential to be used as a single or combination therapy especially chemotherapy for patients with cervical cancer.

Article Details

Author Biography

Andi Yasmon, Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Andi Yasmon

Assistant Professor

 

  • Faculty of Medicine, Department of Microbiology Clinic
  • 2006 to present | Teacher and Researcher (Department of Microbiology Faculty of Medicine) Focusing in Molecular Microbiology in Bacteriology, Virology dan Mycology, Emerging Disease and Probiotic
  • H-Index 6 
  • PUBLIKASI JURNAL INTERNATIONAL
  • Ambar K Astuti, Andi Yasmon, Melva Louisa, Puspita Eka Wuyung, Jumpei Washio, Nobuhiro Takahashi, Yuniardini Septorini Wimardhani. Characterization of Lactococcus lactissubspecies lactis strain Y-PDH01-07 isolated from traditional Indonesian fermented milk (dadih) as an oral probiotic candidate. Science Progress 2025; 108(4): 1–22.
  • Meutia Gebrina, Alvina Widhani, Rudi Putranto, Murdani Abdullah, Ikhwan Rinaldi, Samsuridjal Djauzi, Fransiscus D. Suyatna, Beti Ernawati Dewi, Andi Yasmon, Susan Rahayu, Amalia Shabrina. Patients with Systemic Lupus Erythematosus with Anxiety or Depression: Clinical Characteristics, Food Intake, and Gut Microbiota Profile. Acta Med Indones-Indones J Intern Med, 2025; 57(3): 295-305.
  • Ambar Kusuma Astuti, Samsul, Melva Louisa, Yuniardini Septorini Wimardhani, Andi Yasmon, and Puspita Eka Wuyung. Clinical and histopathological evaluation of 5-fluorouracil-induced oral mucositis in a rat model. Open Veterinary Journal, 2025, 15(5): 1958-1968

References

World Health Organization (WHO) International Agency for Research on Cancer (IARC), Global Cancer Observatory. Indonesia Fact Sheet, 2022. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf

Mlynarczyk-Bonikowska B, Rudnicka L. HPV Infections—Classification, Pathogenesis, and Potential New Therapies. Int J Mol Sci. 2024.25(14):7616. doi: 10.3390/ijms25147616

Habtemariam LW, Zewde ET, Simegn GL. Cervix Type and Cervical Cancer Classification System Using Deep Learning Techniques. Medical Devices: Evidence and Research. 2022;15:163–76. doi: 10.2147/MDER.S366303

Ghosh I, Mandal R, Kundu P, Biswas J. Association of genital infections other than human papillomavirus with pre-invasive and invasive cervical neoplasia. Journal of Clinical and Diagnostic Research. 2016 Feb 1;10(2):01–6. doi: 10.7860/JCDR/2016/15305.7173

Nelson CW, Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Research. 2023. 15:200-258 doi: 10.1016/j.tvr.2023.200258

Jiang Z, Albanese J, Kesterson J, Warrick J, Karabakhtsian R, Dadachova E, et al. Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer. Transl Oncol. 2019 Oct 1;12(10):1289–95. doi: 10.1016/j.tranon.2019.06.003

National Cancer Institute. Human Papillomavirus (HPV) Vaccines. National Cancer Institute. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet

Aghbash PS, Hemmat N, Fathi H, Baghi HB. Monoclonal antibodies in cervical malignancy-related HPV. Front Oncol. 2022;6:12:904790. doi: 10.3389/fonc.2022.904790

Yan F, Cowell LG, Tomkies A, Day AT. Therapeutic Vaccination for HPV-Mediated Cancers. Current Otorhinolaryngology Reports. 2023; 11(1):44-61. doi: 10.1007/s40136-023-00443-8

Rodríguez-Nava C, Ortuño-Pineda C, Illades-Aguiar B, Flores-Alfaro E, Leyva-Vázquez MA, Parra-Rojas I, et al. Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer. Biomedicines. 2023;11(6):1610. doi: 10.3390/biomedicines11061610

Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014;370(8):734–43. doi: 10.1056/NEJMoa1309748

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 2021;385(20):56–67. doi: 10.1056/NEJMoa2112435

Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024;391(1):44–55. doi: 10.1056/NEJMoa2313811

Ryu WS. Molecular virology of human pathogenic viruses. Academic Press; 2017.

Yu L, Majerciak V, Zheng ZM. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int. J. Mol. Sci. 2022;23(9): 4943. doi: 10.3390/ijms23094943

Yu L, Majerciak V, Zheng ZM. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int. J. Mol. Sci. 2022. 23(9): 4943. doi: 10.3390/ijms23094943

Novalia V. Kanker Serviks. Galenical Jurnal Kedokteran dan Kesehatan Mahasiswa Malikussaleh. 2023;2(1):45-56. doi: 10.29103/jkkmm.v2i1.10134

Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. J. Virus Research. 2017;:231:21-33. doi: 10.1016/j.virusres.2016.11.023

Westrich JA, Vermeer DW, Colbert PL, Spanos WC, Pyeon D. The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses. Mol Carcinog. 2020;59(7):794–806. doi: 10.1002/mc.23188

Hasan UA, Zannetti C, Parroche P, Goutagny N, Malfroy M, Roblot G, et al. The Human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. Journal of Experimental Medicine. 2013;210(7):1369–87. doi: 10.1084/jem.20122394

Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018;379(20):1895–904. doi: 10.1056/NEJMoa1806395

Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Research. 2022. 13: 200-238. doi: 10.1016/j.tvr.2022.200238

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ. 2018;1:363. doi: 10.1016/j.intimp.2022.108848

Alejandra WP, Miriam Irene JP, Fabio Antonio GS, Patricia RGR, Elizabeth TA, Juan Pablo AA, et al. Production of monoclonal antibodies for therapeutic purposes: A review. International Immunopharmacology. 2023. 120:110-376. doi: 10.1016/j.intimp.2023.110376

Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, et al. Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: Toward personalized medicine and combination strategies. J Immunol Res. 2018:6984948. doi: 10.1155/2018/6984948

Gerriets V, Kasi A. Bevacizumab. [Updated 2023 Aug 28]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482126/

Sari NFP, Santi MDS, Furwanti C, Pratama AM, Ulfa F. Review of Clinical Use Of Monoclonal Antibodies (Bevacizumab). World Journal of Pharmaceutical Research. 2022;11(11):36-45.

Noordhuis MG, Eijsink JJH, Ten Hoor KA, Roossink F, Hollema H, Arts HJG, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (Chemo)radiation and survival in cervical cancer. Clinical Cancer Research. 2009 Dec 1;15(23):7389–97. doi: 10.1158/1078-0432.CCR-09-1149

Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncology. 2015;11(6): 909-922. doi: 10.2217/fon.14.276

Xing Y, Yasinjan F, Du Y, Geng H, Zhang Y, He M, et al. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials. Front Immunol. 2023.3;14: 1094437. DOI: 10.3389/fimmu.2023.1094437

Clark KT, Trimble CL. Current status of therapeutic HPV vaccines. Gynecologic Oncology. 2020; 156(2):503–510. doi: 10.1016/j.ygyno.2019.12.017

Rumfiled CS, Schlom J, Jochems C. Combination Therapies for HPV-Associated Malignancies. J Clin Cell Immunol. 2021;12(1):608.

Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obst Gynecol. 2016;214(1):22–30. DOI: 10.1016/j.ajog.2015.07.022

Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020.9(3):20-34. DOI: 10.3390/antib9030034